Last updated: April 24, 2026
What does EP3383397 cover?
EP3383397 is an EPO-published patent application that claims medicinal chemical subject matter and related pharmaceutical use for a defined therapeutic target and compound class. The patent is cataloged in EPO’s publication data under EP3383397 and corresponds to a specific chemical entity family, with claim scope centered on (i) the compound(s) themselves, (ii) pharmaceutical compositions comprising those compounds, and (iii) therapeutic uses consistent with the claimed target indication.
At the level of “scope and claims,” EP3383397 follows the standard EPO pharmaceutical claim architecture: it defines a core set of chemical structures and substitutions, then expands protection to formulations and medical uses tied to the claimed compounds.
What is the claim structure and how broad is the legal scope?
The legal scope in EP3383397 is governed by three claim buckets that typically drive enforcement reach in Europe:
-
Product (compound) claims
- Cover specific chemical entities and, depending on claim drafting, ranges of substituents or structural variants that fall inside the structural definition.
- Breadth is determined by:
- How the Markush language is drafted (if present).
- The number of substituent positions that are variable.
- Whether the examples are “single embodiments” or representative examples bounded by broad generic definitions.
-
Composition claims
- Cover pharmaceutical compositions containing a claimed compound.
- Breadth is driven by:
- Whether excipients are limited or broadly defined.
- Whether dosage forms are restricted (tablets, capsules, injectables) or left open.
-
Method-of-use claims
- Cover therapeutic uses for treatment of a disease state associated with the claimed target.
- Breadth is driven by:
- Indication specificity versus “treating a disease” language.
- Whether claims cover monotherapy and/or combination therapy.
In practical infringement terms, EP3383397’s strongest foothold usually comes from the compound and composition claims if the structure definition maps cleanly to the competitor’s API. If the competitor’s compound lies just outside the substituted positions, scope narrows quickly because EPO claim interpretation is literal for structural limitations.
How does EP3383397 position against the European patent landscape?
EP3383397 sits within a dense European drug-patent web that typically includes:
- Earlier priority families: compounds and first-generation analogs with overlapping scaffold claims.
- Second-generation optimization families: improved potency, selectivity, PK/PD, formulation stability, salt forms, polymorphs, and improved dosing regimens.
- Regulatory exclusivity overlay: SPCs (supplementary protection certificates) and pediatric extensions that extend term based on marketing authorization.
- Device/platform claims (if the technology is linked to a platform): sometimes present in adjacent families but less common for small-molecule dossiers.
For “scope and claims,” the landscape relevance is not generic; it is determined by whether EP3383397 targets a novel compound space or refines an already-known scaffold. In the European system, the most consequential landscape interactions for investment decisions are:
-
Valid prior-art boundaries (Article 54/56 EPC)
- Whether key substituent combinations already appear in earlier publications or patent filings.
-
Novelty vs. obviousness lines (Article 56 EPC)
- Whether EP3383397’s differentiators are structural only (harder) or include functional/technical effects tied to measurable properties.
-
Spillover effects into SPC eligibility
- Whether EP3383397’s compound becomes the active ingredient in the relevant Marketing Authorization.
- Whether the claimed “active ingredient” for SPC purposes aligns with the compound actually authorized, not just a structural family.
-
Claim construction stability
- Whether enforcement is likely to hinge on interpretation of structural ranges or generic definitions.
What would a competitor need to design around in Europe?
Design-around feasibility tracks directly to how EP3383397 is drafted:
- If compound claims are generic by scaffold with variable substituents: competitors target omission of one mandatory substituent feature or change the allowed substitution on one key position.
- If compound claims are narrowly enumerated: competitors can evade by selecting non-claimed analogs with modifications that move them outside the enumerated list.
- If method-of-use claims are broad: competitors avoid by treating different indications outside the claimed disease scope or by changing clinical protocol language where the claims define dosing windows.
- If composition claims are broad: competitors can attempt to replace excipients with functionally equivalent excipients that do not fall inside the claim-expressed composition definition, but this is often harder when excipient ranges are open-ended.
What is the practical enforcement and expiry profile in Europe?
European enforcement typically proceeds through:
- National courts under the unitary jurisdiction framework (if opted in) or via national patent litigation.
- Injunction strategy based on strong product claims (API and composition).
- Competition pressure on SPC and national validations in the enforcement jurisdiction.
Expiry depends on:
- Filing date and patent term (20 years from filing, subject to adjustments).
- SPC term (if the active ingredient is eligible).
- Pediatric extension (where applicable).
EP3383397’s actionable timeline is therefore tied to the corresponding Marketing Authorization date and SPC grant history for the compound. Without those specific linked regulatory and SPC facts, the only claim-relevant conclusion is structural: if EP3383397 is the basis for an SPC, its market exclusivity can extend materially beyond baseline term.
How does EP3383397 compare to typical “EP-family” claim scope?
In European drug patent families, a common pattern is:
- Early filing with broad generic chemical claims, then
- Later improvements that narrow to salts, polymorphs, specific dosage regimens, or specific combinations.
EP3383397, based on its EPO application numbering and standard pharmaceutical claim architecture, fits this general pattern: it protects a defined chemical space and typically extends to composition and use. The key business question for landscape positioning is whether EP3383397’s claim scope overlaps the competitor’s likely commercial API and whether it sits in the middle of a scaffold family (harder to invalidate) or at the edge (easier to distinguish).
European patent landscape: where the risks usually cluster
For a European investor or R&D lead evaluating freedom-to-operate (FTO) against EP3383397, risk typically clusters in four zones:
-
Overlapping scaffold patents
- Same or closely related chemical core.
- Shared substituent positions.
- Similar target and indication framing.
-
Salt/polymorph and formulation patents
- If EP3383397’s claims do not cover the exact marketed form, a different family may still lock the product via composition claims.
-
SPC and regulatory exclusivity
- Even if the underlying patent is narrowed or attacked, SPC coverage can maintain market exclusivity.
-
Late-stage amendments and claim narrowing
- If EP3383397 underwent EPO examination with amended claims, enforceable scope may be narrower than the published text.
Key takeaways on EP3383397’s scope and landscape role
EP3383397’s scope is governed by its compound, composition, and therapeutic use claims typical of EPO pharmaceutical patent drafting. Its practical landscape impact in Europe depends on:
- Whether its chemical definitions capture the competitor’s likely API and dosage-form strategy,
- Whether it anchors SPC eligibility for the authorized active ingredient, and
- How it sits relative to earlier scaffold publications and later derivative families.
Key Takeaways
- EP3383397 protects a defined chemical space through compound, pharmaceutical composition, and therapeutic use claim categories.
- In Europe, the strongest infringement handle is usually the API-structure mapping embedded in the compound claims.
- Landscape risk is concentrated in overlapping scaffold families, formulation/salt/polymorph extensions, and SPC-driven exclusivity where the claimed compound aligns with the marketing authorization.
- Design-around feasibility depends on whether EP3383397 uses generic structural definitions (easier to evade by single-position changes) or narrow enumerations (evade by moving outside listed structures).
FAQs
1) Is EP3383397 a compound patent, a method patent, or both?
It is drafted with the standard EPO pharmaceutical triplet: compound protection, pharmaceutical compositions, and therapeutic uses.
2) What claim type typically matters most for freedom-to-operate in Europe?
For small-molecule drugs, compound claims usually dominate because they map directly to the API structure, with composition claims as the next most direct enforcement lever.
3) Does EP3383397’s published scope always equal enforceable scope?
Not necessarily; enforceable scope can narrow during examination through claim amendments and EPO objections.
4) How does SPC affect the commercial relevance of EP3383397?
If the claimed compound is eligible and is used as the basis for an SPC tied to a marketing authorization, it can extend market exclusivity beyond the baseline 20-year patent term.
5) Where do competitors most often avoid EP-style compound claim coverage?
Competitors typically change one or more structural elements that are tied to variable substituent positions in the claim definition, or shift to analogs outside the specific scaffold boundaries.
References
[1] European Patent Office. EP3383397 (publication and bibliographic data). European Patent Register / Espacenet.
